As Biogen Inc., Merck & Co. Inc. and Eli Lilly and Co. race to the finish line with their Alzheimer’s disease drugs that are in phase III development, two companies – Neuro-Bio Ltd. and Ironwood Pharmaceuticals Inc. – are just lacing up their shoes.